Tempest rises on positive FDA feedback for cancer therapy study

Tempest Therapeutics

15/08/2024 14:36

** Shares of cancer drug developer Tempest Therapeutics
 TPST.O  rise 8.4% to $1.29 
    ** TPST says the U.S. FDA has agreed to the proposed design
for a late-stage study testing co's experimental combination
therapy as first-line treatment for a type of unresectable or
metastatic liver cancer
    ** TPST plans to begin the study testing its drug candidate
amezalpat in combination with Roche's  ROG.S  Avastin and
Tecentriq in Q1 2025  
    ** Says amezalpat is designed to target tumor cells directly
and modulate immune suppressive cells
    ** Including session gains, stock down ~71% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))